Retraction: RETRACTED: Chronic Administration of Carbamazepine Down-regulates AP-2 DNA-binding Activity and AP-2a Protein Expression in Rat Frontal Cortex (Biological Psychiatry (2007) 61(2) (154–161)(S0006322306004367)(10.1016/j.biopsych.2006.03.029));Chronic Administration of Carbamazepine Down-regulates AP-2 DNA-binding Activity and AP-2α Protein Expression in Rat Frontal Cortex

Biological Psychiatry

Volumn 61, Issue 2, 2007, Pages 154-161

  Rao, Jagadeesh S ^a   Bazinet, Richard P ^a   Rapoport, Stanley I ^a   Lee, Ho Joo ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

AP 2; AP 2 ; arachidonic acid; bipolar disorder; brain; carbamazepine; NF B; phospholipase A2; PKA; PKC; transcription factors

Indexed keywords

CARBAMAZEPINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN SUBUNIT; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2ALPHA; TRANSCRIPTION FACTOR PEA3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASSAY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; FRONTAL CORTEX; HYPOTHESIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; RAT;

EID: 33846052018     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2016.10.015     Document Type: Erratum

References (39)

1. Adams S.R., Harootunian A.T., Buechler Y.J., Taylor S.S., and Tsien R.Y. Fluorescence ratio imaging of cyclic AMP in single cells. Nature 349 (1991) 694-697
2. Arnone D. Review of the use of Topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 4 (2005) 1-5
3. Axelrod J. Receptor-mediated activation of phospholipase A2 and arachidonic acid release in signal transduction. Biochem Soc Trans 18 (1990) 503-507
4. Baf M.H., Subhash M.N., Lakshmana K.M., and Rao B.S. Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem Int 24 (1994) 67-72
5. Bazinet R.P., Rao J.S., Chang L., Rapoport S.I., and Lee H.J. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: Relevance to bipolar disorder. Biol Psychiatry 59 (2006) 401-407
6. Bazinet R.P., Weis M.T., Rapoport S.I., and Rosenberger T.A. Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by microsomal long-chain fatty acyl-CoA synthetases: Relevance to bipolar disorder. Psychopharmacology (Berl) 184 (2006) 122-129
7. Bialer M., Levy R.H., and Perucca E. Does carbamazepine have a narrow therapeutic plasma concentration range?. Ther Drug Monit 20 (1998) 56-59
8. Bosetti F., Rintala J., Seemann R., Rosenberger T.A., Contreras M.A., Rapoport S.I., et al. Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol Psychiatry 7 (2002) 845-850
9. Bosetti F., Weerasinghe G.R., Rosenberger T.A., and Rapoport S.I. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J Neurochem 85 (2003) 690-696
10. Bown C.D., Wang J.F., and Young L.T. Attenuation of N-methyl-D-aspartate-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers. Neuroscience 117 (2003) 949-955
11. Chang A., Li P.P., and Warsh J.J. Altered cAMP-dependent protein kinase subunit immunolabeling in post-mortem brain from patients with bipolar affective disorder. J Neurochem 84 (2003) 781-791
12. Chang A., Li P.P., and Warsh J.J. cAMP-Dependent protein kinase (PKA) subunit mRNA levels in postmortem brain from patients with bipolar affective disorder (BD). Brain Res Mol Brain Res 116 (2003) 27-37
13. Chang M.C., Contreras M.A., Rosenberger T.A., Rintala J.J., Bell J.M., and Rapoport S.I. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: A possible common effect of mood stabilizers. J Neurochem 77 (2001) 796-803
14. Chang M.C., Grange E., Rabin O., Bell J.M., Allen D.D., and Rapoport S.I. Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci Lett 220 (1996) 171-174
15. Chang M.C., and Jones C.R. Chronic lithium treatment decreases brain phospholipase A2 activity. Neurochem Res 23 (1998) 887-892
16. Chen G., Pan B., Hawver D.B., Wright C.B., Potter W.Z., and Manji H.K. Attenuation of cyclic AMP production by carbamazepine. J Neurochem 67 (1996) 2079-2086
17. Damberg M., Eller M., Tonissaar M., Oreland L., and Harro J. Levels of transcription factors AP-2alpha and AP-2beta in the brainstem are correlated to monoamine turnover in the rat forebrain. Neurosci Lett 313 (2001) 102-104
18. Garcia M.A., Campillos M., Marina A., Valdivieso F., and Vazquez J. Transcription factor AP-2 activity is modulated by protein kinase A-mediated phosphorylation. FEBS Lett 444 (1999) 27-31
19. Ghelardoni S., Bazinet R.P., Rapoport S.I., and Bosetti F. Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism. Psychopharmacology (Berl) 180 (2005) 523-529
20. Ghelardoni S., Tomita Y.A., Bell J.M., Rapoport S.I., and Bosetti F. Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biol Psychiatry 56 (2004) 248-254
21. Harootunian A.T., Adams S.R., Wen W., Meinkoth J.L., Taylor S.S., and Tsien R.Y. Movement of the free catalytic subunit of cAMP-dependent protein kinase into and out of the nucleus can be explained by diffusion. Mol Biol Cell 4 (1993) 993-1002
22. Hasegawa H., Osada K., Misonoo A., Morinobu S., Yamamoto H., Miyamoto E., et al. Chronic carbamazepine treatment increases myristoylated alanine-rich C kinase substrate phosphorylation in the rat cerebral cortex via down-regulation of calcineurin A alpha. Brain Res 994 (2003) 19-26
23. Imagawa M., Chiu R., and Karin M. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: Protein kinase C and cAMP. Cell 51 (1987) 251-260
24. Jakobsen S.N., and Wiborg O. Selective effects of long-term lithium and carbamazepine administration on G-protein subunit expression in rat brain. Brain Res 780 (1998) 46-55
25. Jensen J.B., and Mork A. Altered protein phosphorylation in the rat brain following chronic lithium and carbamazepine treatments. Eur Neuropsychopharmacol 7 (1997) 173-179
26. Karege F., Schwald M., Papadimitriou P., Lachausse C., and Cisse M. The cAMP-dependent protein kinase A and brain-derived neurotrophic factor expression in lymphoblast cells of bipolar affective disorder. J Affect Disord 79 (2004) 187-192
27. Koide H., Ogita K., Kikkawa U., and Nishizuka Y. Isolation and characterization of the epsilon subspecies of protein kinase C from rat brain. Proc Natl Acad Sci U S A 89 (1992) 1149-1153
28. Lee H., Ghelardoni S., Chang L., Bosetti F., Rapoport S., and Bazinet R.P. Topiramate does not alter the kinetics of arachidonic or docosahexaenoic acid in brain phospholipids of the unanesthetized rat. Neurochem Res 30 (2005) 677-683
29. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
30. Morri H., Ozaki M., and Watanabe Y. 5′-flanking region surrounding a human cytosolic phospholipase A2 gene. Biochem Biophys Res Commun 205 (1994) 6-11
31. Moser M., Ruschoff J., and Buettner R. Comparative analysis of AP-2 alpha and AP-2 beta gene expression during murine embryogenesis. Dev Dyn 208 (1997) 115-124
32. Perez J., Tardito D., Racagni G., Smeraldi E., and Zanardi R. cAMP signaling pathway in depressed patients with psychotic features. Mol Psychiatry 7 (2002) 208-212
33. Post R.M., Frye M.A., Denicoff K.D., Leverich G.S., Kimbrell T.A., and Dunn R.T. Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology 19 (1998) 206-219
34. Rao JS, Bazinet RP, Rapoport SI, Lee H-J (in press): Chronic treatment with sodium valproate downregulates frontal cortex NF-κB DNA binding activity and COX-2 mRNA. Bipolar Disord.
35. Rao J.S., Rapoport S.I., and Bosetti F. Decrease in the AP-2 DNA-binding activity and in the protein expression of AP-2 alpha and AP-2 beta in frontal cortex of rats treated with lithium for 6 weeks. Neuropsychopharmacology 30 (2005) 2006-2013
36. Rintala J., Seemann R., Chandrasekaran K., Rosenberger T.A., Chang L., Contreras M.A., et al. 85 kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain. Neuroreport 10 (1999) 3887-3890
37. Sachs G.S., Kushner S.F., Wang D., Olson W., Capece J., Fazzio L., et al. Topiramate in adults with acute bipolar I mania: pooled results (2004), American Psychiatric Association, Arlington VA American Psychiatric Association, Annual Meeting Abstract number-NR365, New York, NY
38. Sun G.Y., Xu J., Jensen M.D., and Simonyi A. Phospholipase A2 in the central nervous system: Implications for neurodegenerative diseases. J Lipid Res 45 (2004) 205-213
39. Tardito D., Mori S., Racagni G., Smeraldi E., Zanardi R., and Perez J. Protein kinase A activity in platelets from patients with bipolar disorder. J Affect Disord 76 (2003) 249-253